2,4-二溴嘧啶 | 3921-01-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2,4-二溴嘧啶
• 英文名称: 2,4-dibromopyrimidine
• CAS: 3921-01-5
• 化学式: C₄H₂Br₂N₂
• 分子量: 237.881
• InChiKey: AOEHEEBFRCAFGC-UHFFFAOYSA-N

物化性质

• 熔点：
  65-67 °C
• 沸点：
  316.6±34.0 °C(Predicted)
• 密度：
  2.197
• 稳定性/保质期：
  在常温常压下，该物质是稳定的。

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT, KEEP COLD, STORED UNDER ARGON
• 危险品标志：
  Xi
• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• 海关编码：
  2933599090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  常温、避光、通风干燥处，密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
2,4-Dibromopyrimidine
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
2,4-Dibromopyrimidine
Ingredient name:
CAS number: 3921-01-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C4H2Br2N2
Molecular weight: 237.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

医药生物化工中间体。

用途简介

反应信息

• 作为反应物：
  描述：

  2,4-二溴嘧啶 在 ammonium hydroxide 作用下， 反应 16.0h， 以54.6%的产率得到2-氨基-4-溴嘧啶
  参考文献：
  名称：

  一种2-氨基-4-溴嘧啶的制备方法

  摘要：

  本发明公开了一种2‑氨基‑4‑溴嘧啶的制备方法，以尿嘧啶、三溴氧磷、氨化试剂等为原料，经过两步反应得到目的产物2‑氨基‑4‑溴嘧啶。本发明操作简便、提纯方便、收率高、成本低，适合工业化规模生产。

  公开号：

  CN106632077B
• 作为产物：
  描述：

  尿嘧啶 在 三溴氧磷 作用下， 反应 2.0h， 以48%的产率得到2,4-二溴嘧啶
  参考文献：
  名称：

  溴代二嗪的金属化。二嗪XL

  摘要：

  改进了2-溴吡嗪，2,4-二溴嘧啶和3-溴-6-苯基吡嗪的合成，并研究了其与烷基酰胺锂的金属化作用。

  DOI：

  10.1002/jhet.5570420406

文献信息

• [EN] DIAZABICYCLONONENE AND TETRAHYDROPYRIDINE DERIVATIVES AS RENIN INHIBITORS<br/>[FR] DERIVES DE DIAZABICYCLONONENE ET DE TETRAHYDROPYRIDINE UTILISES COMME INHIBITEURS DE LA RENINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004096804A1

  公开（公告）日：2004-11-11

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives, tetrahydropyridine derivatives, and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors of renin.

  本发明涉及新型的3,9-二氮杂双环[3.3.1]壬烯衍生物、四氢吡啶衍生物及其相关化合物，以及它们作为活性成分用于制备药物组合物的用途。本发明还涉及相关方面，包括制备这些化合物的方法、含有一种或多种这些化合物的药物组合物，尤其是它们作为肾素抑制剂的用途。
• [EN] INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE LA PROTÉINE KINASE I INTERAGISSANT AVEC LE RÉCEPTEUR POUR LE TRAITEMENT D'UNE MALADIE
  申请人：UNIV TEXAS

  公开号：WO2021173917A1

  公开（公告）日：2021-09-02

  Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

  公开了抑制RIPK1的化合物，药物组合物以及治疗RIPK1介导的疾病的方法，如神经退行性疾病，炎症性疾病和癌症。
• Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells via Cell Cycle Perturbation
  作者：Seung-Youn Jung、Ky-Youb Nam、Jeong-In Park、Kyung-Hee Song、Jiyeon Ahn、Jong Kuk Park、Hong-Duck Um、Sang-Gu Hwang、Sang Un Choi、Jie-Young Song

  DOI：10.1124/jpet.119.257717

  日期：2019.9

  radiosensitizers to improve the therapeutic outcomes of radiotherapy in cancer patients. Our previous efforts to identify novel radiosensitizers, using high-throughput screening targeting p53 and Nrf2 revealed a promising N-phenylpyrimidin-2-amine (PPA) lead compound. In the present study, 17 derivatives of this lead compound were examined, and it was found that 4-(4-fluorophenyl)-N-(4-nitrophenyl)-6-phenylpyrimidin-2-amine

  放射疗法是最常见的癌症治疗方法之一，但是放射抵抗和对正常组织的损伤被认为是成功放射疗法的主要障碍。因此，迫切需要开发放射增敏剂以改善癌症患者中放射疗法的治疗结果。我们以前使用针对p53和Nrf2的高通量筛选来鉴定新型放射增敏剂的努力揭示了一种有前途的N-苯基嘧啶-2-胺（PPA）铅化合物。在本研究中，研究了该先导化合物的17种衍生物，发现4-（4-氟苯基）-N-（4-硝基苯基）-6-苯基嘧啶-2-胺（PPA5），4-（（ 4-（4-氟苯基）嘧啶-2-基）氨基）-3-甲氧基-N-甲基-苯甲酰胺（PPA13），4-（（4-（4-氟苯基）嘧啶-2-基）氨基）苯磺酰胺（ PPA14），4-（（4-（2-氯苯基）嘧啶-2-基）氨基）苯磺酰胺（PPA15）和4-（（4-（2-氯苯基）嘧啶-2-基）氨基）-N-甲基苯甲酰胺（PPA17 ）将细胞活力抑制了50％以上，并且在细胞周期的G2 / M期停滞的细
• [EN] SREBP INHIBITORS COMPRISING A 6-MEMBERED CENTRAL RING<br/>[FR] INHIBITEURS DE SREBP COMPRENANT UN NOYAU CENTRAL À 6 CHAÎNONS
  申请人：CAPULUS THERAPEUTICS LLC

  公开号：WO2019148125A1

  公开（公告）日：2019-08-01

  Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formula (I), Formula (I-A), Formula (I-Ai), Formula (I-B), and Formula (I-Bi), and pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Also provided herein are methods of inhibiting a component of the sterol regulatory element binding protein (SREBP) pathway, such as an SREBP or SREBP cleavage activating protein (SCAP), using these compounds, or pharmaceutically acceptable salts, solvates, tautomers, isotopes, or isomers thereof. Further provided are methods of treating a disorder in a subject in need thereof, such as liver disease, non-alcoholic steatohepatitis, insulin resistance, or cancer.

  本文提供了包含三环核的化合物，例如Formula（X），Formula（X-A），Formula（X-Ai），Formula（X-B），Formula（X-Bi），Formula（Z），Formula（Z-A），Formula（Z-Ai），Formula（Z-B），Formula（Z-Bi），Formula（I），Formula（I-A），Formula（I-Ai），Formula（I-B）和Formula（I-Bi），以及其药学上可接受的盐类、溶剂化合物、互变异构体、同位素或同分异构体。本文还提供了利用这些化合物或其药学上可接受的盐类、溶剂化合物、互变异构体、同位素或同分异构体来抑制类固醇调节元件结合蛋白（SREBP）途径的组分的方法，例如SREBP或SREBP裂解激活蛋白（SCAP）。此外，还提供了治疗患有肝病、非酒精性脂肪肝病、胰岛素抵抗或癌症等疾病的方法。
• Synthesis of Bis-heteroaryls Using Grignard Reagents and Pyridylsulfonium Salts
  作者：Alexandra M. Horan、Vincent K. Duong、Eoghan M. McGarrigle

  DOI：10.1021/acs.orglett.1c03379

  日期：2021.12.3

  reported ligand-coupling reactions of Grignard reagents with pyridylsulfonium salts. The method has wide functional group tolerance and enables the formation of bis-heterocycle linkages, including 2,4′-, 2,3′-, and 2,2′-bipyridines, as well as pyridines linked to pyrimidines, pyrazines, isoxazoles, and benzothiophenes. The methodology was successfully applied to the synthesis of the natural products caerulomycin

  本文报道了格氏试剂与吡啶基锍盐的配体偶联反应。该方法具有广泛的官能团耐受性，能够形成双杂环键，包括 2,4'-、2,3'-和 2,2'-联吡啶，以及与嘧啶、吡嗪、异恶唑连接的吡啶，和苯并噻吩。该方法成功地应用于天然产物 caerulomycin A 和 E 的合成。